摘要
Intrahepatic cholangiocarcinoma (iCCA) is a deadly malignancy with limited treatment options. Gain-of-function mutations in K-Ras is a very frequent alteration, occurring in similar to 15 to 25% of human iCCA patients. Here, we established a new iCCA model by expressing activated forms of Notch1 (NICD) and K-Ras (K-Ras(V12D)) in the mouse liver (K-Ras/NICD mice). Furthermore, we investigated the therapeutic potential of MEK inhibitors in vitro and in vivo using human CCA cell lines and K-Ras/NICD mice, respectively. Treatment with U0126, PD901, and Selumetinib MEK inhibitors triggered growth restraint in all CCA cell lines tested, with the most pronounced growth suppressive effects being observed in K-Ras mutant cells. Growth inhibition was due to reduction in proliferation and massive apoptosis. Furthermore, treatment of K-Ras/NICD tumor-bearing mice with PD901 resulted in stable disease. At the molecular level, PD901 efficiently inhibited ERK activation in K-Ras/NICD tumor cells, mainly leading to increased apoptosis. Altogether, our study demonstrates that K-Ras/NICD mice represent a novel and useful preclinical model to study K-Ras-driven iCCA development and the effectiveness of MEK inhibitors in counteracting this process. Our data support the usefulness of MEK inhibitors for the treatment of human iCCA.
| 源语言 | 英语 |
|---|---|
| 页数 | 13 |
| 期刊 | CELL DEATH & DISEASE |
| 卷 | 9 |
| DOI | |
| 出版状态 | 已出版 - 18 1月 2018 |
基金资助
We like to thank Dr Allan Balmain of UCSF for providing LSL-K-RasG12D mice. This work is supported by NIH grants R01CA190606 to X.C.; and P30DK026743 for UCSF Liver Center; as well as grant from Cholangiocarcinoma Foundation to J.G.
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
-
可持续发展目标 3 良好健康与福祉
收录
- SCIE
学术指纹
探究 'Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver